Comparative study of Valsartan and Leucovorin alone or in combination for renal protection in methotrexate-induced acute kidney injury in rats
Open Access
- 31 March 2026
- journal article
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 39 (1) , 53
Abstract
Methotrexate (MTX) is a widely used chemotherapeutic and immunosuppressive agent that may induce acute kidney injury (AKI), posing a major clinical challenge. This study investigated the renoprotective effects of Valsartan, Leucovorin and their combination in mitigating methotrexate (MTX)-induced renal damage in Wistar rats. The aim was to evaluate these effects in a rat model of MTX-induced acute kidney injury (AKI). After approval by the Institutional Animal Ethics Committee (IAEC), forty male Wistar rats were divided into five groups: control (saline), MTX (single intraperitoneal injection of 20 mg/kg), Valsartan (10 mg/kg/day), leucovorin (10 mg/kg/day), and combination (Valsartan plus leucovorin). Drug treatment was initiated one day before MTX administration and continued orally for five days. Renal function was assessed by measuring serum creatinine and blood urea nitrogen (BUN). Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were evaluated as inflammatory markers, while malondialdehyde (MDA) and glutathione (GSH) were assessed as oxidative stress markers. Histopathological examination of renal tissue was also performed. Data were analyzed using GraphPad Prism version 6. The MTX group showed significant renal dysfunction (p < 0.001) and increased inflammatory and oxidative stress markers. Both Valsartan and leucovorin produced partial renoprotective effects, with Valsartan significantly reducing oxidative stress (p < 0.001) and leucovorin markedly decreasing inflammatory markers (p < 0.001). The combination therapy demonstrated the most pronounced renoprotective effect (p < 0.001), as evidenced by improved renal function and reduced oxidative damage and inflammation. Histopathological analysis revealed decreased tubular necrosis and inflammatory infiltration in the combination group. Valsartan and leucovorin exerted individual renoprotective effects; however, their combined administration provided highly significant protection against MTX-induced AKI. These findings suggest that combination therapy may represent a promising strategy for preventing renal injury in patients undergoing MTX treatment.Keywords
This publication has 14 references indexed in Scilit:
- Leucovorin (folinic acid) rescue for high‐dose methotrexate: A reviewJournal of Clinical Pharmacy and Therapeutics, 2022
- Management of Patients with Acute Methotrexate Nephrotoxicity with High‐Dose LeucovorinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- Protective effects of aliskiren and valsartan in mice with diabetic nephropathyJournal of the Renin-Angiotensin-Aldosterone System, 2014
- Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritisCochrane Database of Systematic Reviews, 2013
- Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytesJournal of the Renin-Angiotensin-Aldosterone System, 2012
- Understanding and Managing Methotrexate NephrotoxicityThe Oncologist, 2006
- Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathyKidney International, 2003
- Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in ratsActa Histochemica, 2002
- Methotrexate for Rheumatoid ArthritisArthritis & Rheumatism, 1994
- The clinical pharmacology of methotrexate.new applications of an old drugCancer, 1978